297 related articles for article (PubMed ID: 23313564)
21. Randomized, placebo-controlled trial of risperidone for acute treatment of bipolar anxiety.
Sheehan DV; McElroy SL; Harnett-Sheehan K; Keck PE; Janavs J; Rogers J; Gonzalez R; Shivakumar G; Suppes T
J Affect Disord; 2009 Jun; 115(3):376-85. PubMed ID: 19042026
[TBL] [Abstract][Full Text] [Related]
22. A randomized, double-blind, placebo-controlled study of ziprasidone monotherapy in bipolar disorder with co-occurring lifetime panic or generalized anxiety disorder.
Suppes T; McElroy SL; Sheehan DV; Hidalgo RB; Cosgrove VE; Gwizdowski IS; Feldman NS
J Clin Psychiatry; 2014 Jan; 75(1):77-84. PubMed ID: 24345758
[TBL] [Abstract][Full Text] [Related]
23. Gender specific associations of serum levels of brain-derived neurotrophic factor in anxiety.
Molendijk ML; Bus BA; Spinhoven P; Penninx BW; Prickaerts J; Oude Voshaar RC; Elzinga BM
World J Biol Psychiatry; 2012 Oct; 13(7):535-43. PubMed ID: 21888560
[TBL] [Abstract][Full Text] [Related]
24. Evaluation of the effect of duloxetine treatment on functioning as measured by the Sheehan disability scale: pooled analysis of data from six randomized, double-blind, placebo-controlled clinical studies.
Mancini M; Sheehan DV; Demyttenaere K; Amore M; Deberdt W; Quail D; Sagman D
Int Clin Psychopharmacol; 2012 Nov; 27(6):298-309. PubMed ID: 22954893
[TBL] [Abstract][Full Text] [Related]
25. Desvenlafaxine 50 and 100 mg/d in the treatment of major depressive disorder: an 8-week, phase III, multicenter, randomized, double-blind, placebo-controlled, parallel-group trial and a post hoc pooled analysis of three studies.
Tourian KA; Padmanabhan SK; Groark J; Brisard C; Farrington D
Clin Ther; 2009 Jun; 31 Pt 1():1405-23. PubMed ID: 19698901
[TBL] [Abstract][Full Text] [Related]
26. Duloxetine: a review of its use in the treatment of generalized anxiety disorder.
Carter NJ; McCormack PL
CNS Drugs; 2009; 23(6):523-41. PubMed ID: 19480470
[TBL] [Abstract][Full Text] [Related]
27. Anxiety does not predict response to duloxetine in major depression: results of a pooled analysis of individual patient data from 11 placebo-controlled trials.
Nelson JC
Depress Anxiety; 2010; 27(1):12-8. PubMed ID: 20013987
[TBL] [Abstract][Full Text] [Related]
28. Duloxetine in the treatment of Major Depressive Disorder: a comparison of efficacy in patients with and without melancholic features.
Mallinckrodt CH; Watkin JG; Liu C; Wohlreich MM; Raskin J
BMC Psychiatry; 2005 Jan; 5():1. PubMed ID: 15631624
[TBL] [Abstract][Full Text] [Related]
29. Validation of the geriatric anxiety inventory in a duloxetine clinical trial for elderly adults with generalized anxiety disorder.
Ball SG; Lipsius S; Escobar R
Int Psychogeriatr; 2015 Sep; 27(9):1533-9. PubMed ID: 25925598
[TBL] [Abstract][Full Text] [Related]
30. A double-blind, multicenter trial comparing duloxetine with placebo in the treatment of fibromyalgia patients with or without major depressive disorder.
Arnold LM; Lu Y; Crofford LJ; Wohlreich M; Detke MJ; Iyengar S; Goldstein DJ
Arthritis Rheum; 2004 Sep; 50(9):2974-84. PubMed ID: 15457467
[TBL] [Abstract][Full Text] [Related]
31. Duloxetine in treatment of anxiety symptoms associated with depression.
Dunner DL; Goldstein DJ; Mallinckrodt C; Lu Y; Detke MJ
Depress Anxiety; 2003; 18(2):53-61. PubMed ID: 12964171
[TBL] [Abstract][Full Text] [Related]
32. Patterns of depressive symptom response in duloxetine-treated outpatients with mild, moderate or more severe depression.
Shelton RC; Prakash A; Mallinckrodt CH; Wohlreich MM; Raskin J; Robinson MJ; Detke MJ
Int J Clin Pract; 2007 Aug; 61(8):1337-48. PubMed ID: 17627710
[TBL] [Abstract][Full Text] [Related]
33. Early improvement during duloxetine treatment of generalized anxiety disorder predicts response and remission at endpoint.
Pollack MH; Kornstein SG; Spann ME; Crits-Christoph P; Raskin J; Russell JM
J Psychiatr Res; 2008 Oct; 42(14):1176-84. PubMed ID: 18348888
[TBL] [Abstract][Full Text] [Related]
34. Serum brain-derived neurotrophic factor (BDNF) levels in patients with panic disorder: as a biological predictor of response to group cognitive behavioral therapy.
Kobayashi K; Shimizu E; Hashimoto K; Mitsumori M; Koike K; Okamura N; Koizumi H; Ohgake S; Matsuzawa D; Zhang L; Nakazato M; Iyo M
Prog Neuropsychopharmacol Biol Psychiatry; 2005 Jun; 29(5):658-63. PubMed ID: 15905010
[TBL] [Abstract][Full Text] [Related]
35. The relationship between functional outcomes and the treatment of anxious and painful somatic symptoms in patients with generalized anxiety disorder.
Sheehan DV; Meyers AL; Prakash A; Robinson MJ; Swindle RW; Russell JM; Mallinckrodt CH
Curr Med Res Opin; 2008 Sep; 24(9):2457-66. PubMed ID: 18662492
[TBL] [Abstract][Full Text] [Related]
36. Gender differences in clinical presentation and response to sertraline treatment of generalized anxiety disorder.
Steiner M; Allgulander C; Ravindran A; Kosar H; Burt T; Austin C
Hum Psychopharmacol; 2005 Jan; 20(1):3-13. PubMed ID: 15551351
[TBL] [Abstract][Full Text] [Related]
37. Efficacy and safety of duloxetine in the treatment of older adult patients with generalized anxiety disorder: a randomized, double-blind, placebo-controlled trial.
Alaka KJ; Noble W; Montejo A; Dueñas H; Munshi A; Strawn JR; Lenox-Smith A; Ahl J; Bidzan L; Dorn B; Ball S
Int J Geriatr Psychiatry; 2014 Sep; 29(9):978-86. PubMed ID: 24644106
[TBL] [Abstract][Full Text] [Related]
38. Onset of action for duloxetine 60 mg once daily: double-blind, placebo-controlled studies.
Brannan SK; Mallinckrodt CH; Detke MJ; Watkin JG; Tollefson GD
J Psychiatr Res; 2005 Mar; 39(2):161-72. PubMed ID: 15589564
[TBL] [Abstract][Full Text] [Related]
39. Assessment of depressive symptoms and functional outcomes in patients with major depressive disorder treated with duloxetine versus placebo: primary outcomes from two trials conducted under the same protocol.
Oakes TM; Myers AL; Marangell LB; Ahl J; Prakash A; Thase ME; Kornstein SG
Hum Psychopharmacol; 2012 Jan; 27(1):47-56. PubMed ID: 22241678
[TBL] [Abstract][Full Text] [Related]
40. Deramciclane in the treatment of generalized anxiety disorder: a placebo-controlled, double-blind, dose-finding study.
Naukkarinen H; Raassina R; Penttinen J; Ahokas A; Jokinen R; Koponen H; Lepola U; Kanerva H; Lehtonen L; Pohjalainen T; Partanen A; Mäki-Ikola O; Rouru J;
Eur Neuropsychopharmacol; 2005 Dec; 15(6):617-23. PubMed ID: 15949921
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
